Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded SemaglutideZacks Investment Research • 02/10/26
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug marketWSJ • 02/09/26
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New TurnInvestopedia • 02/09/26
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injectionsCNBC • 02/09/26
Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know.The Motley Fool • 02/08/26
Heard on the Street: : The obesity-market price war has turned traditional pharma economics upside down.WSJ • 02/07/26